For instance, Belzutifan has been approved clinically as a second-generation specific HIF-2α inhibitor for patients with Von Hippel–Lindau (VHL) syndrome to treat associated clear cell renal carcinoma and central nervous system hemangioblastomas [173]. The gene discussed is EPAS1; the disease is clear cell renal carcinoma.